TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling

• Published in: Journal of experimental & clinical cancer research Vol. 42; no. 1; p. 190
• Main Authors: Xu, Teng, Yang, Yuemei, Chen, Zhihong, Wang, Jinsong, Wang, Xiaolei, Zheng, Yang, Wang, Chao, Wang, Yachen, Zhu, Zaiou, Ding, Xu, Zhou, Junbo, Li, Gang, Zhang, Hongchuang, Zhang, Wei, Wu, Yunong, Song, Xiaomeng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 01.08.2023; BioMed Central; BMC
• Subjects: Analysis; Animals; Antimitotic agents; Antineoplastic agents; Antioxidants; Apoptosis; Cancer; Cancer therapies; Cell Line, Tumor; Cells; Chemotherapy; Cisplatin - pharmacology; Cisplatin resistant; Cytokines - metabolism; Disease Models, Animal; Drinking water; Drug Resistance, Neoplasm - genetics; Head & neck cancer; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - genetics; Head and neck squamous cell carcinoma; Humans; KEAP1/NRF2; Kelch-Like ECH-Associated Protein 1 - genetics; Kelch-Like ECH-Associated Protein 1 - metabolism; Kinases; Mass spectrometry; Mice; Mice, Inbred C57BL; Mice, Nude; NF-E2-Related Factor 2 - metabolism; Oxidative stress; Proteins; Reactive Oxygen Species - metabolism; Scientific imaging; Software; Squamous cell carcinoma; Squamous Cell Carcinoma of Head and Neck - drug therapy; Squamous Cell Carcinoma of Head and Neck - genetics; TNFAIP2; Tumor necrosis factor; China; United States > US; TNFAIP2; Oxidative stress; Head and neck squamous cell carcinoma; KEAP1/NRF2; Cisplatin resistant
• ISSN: 1756-9966; 0392-9078; 1756-9966
• DOI: 10.1186/s13046-023-02775-1

Drug resistance limits the treatment effect of cisplatin-based chemotherapy in head and neck squamous cell carcinoma (HNSCC), and the underlying mechanism is not fully understood. The aim of this study was to explore the cause of cisplatin resistance in HNSCC. We performed survival and gene set variation analyses based on HNSCC cohorts and identified the critical role of tumor necrosis factor alpha-induced protein 2 (TNFAIP2) in cisplatin-based chemotherapy resistance. Half-maximal inhibitory concentration (IC50) examination, colony formation assays and flow cytometry assays were conducted to examine the role of TNFAIP2 in vitro, while xenograft models in nude mice and 4-nitroquinoline N-oxide (4NQO)-induced HNSCC models in C57BL/6 mice were adopted to verify the effect of TNFAIP2 in vivo. Gene set enrichment analysis (GSEA) and coimmunoprecipitation coupled with mass spectrometry (Co-IP/MS) were performed to determine the mechanism by which TNFAIP2 promotes cisplatin resistance. High expression of TNFAIP2 is associated with a poor prognosis, cisplatin resistance, and low reactive oxygen species (ROS) levels in HNSCC. Specifically, it protects cancer cells from cisplatin-induced apoptosis by inhibiting ROS-mediated c-JUN N-terminal kinase (JNK) phosphorylation. Mechanistically, the DLG motif contained in TNFAIP2 competes with nuclear factor-erythroid 2-related factor 2 (NRF2) by directly binding to the Kelch domain of Kelch-like ECH-associated protein 1 (KEAP1), which prevents NRF2 from undergoing ubiquitin proteasome-mediated degradation. This results in the accumulation of NRF2 and confers cisplatin resistance. Positive correlations between TNFAIP2 protein levels and NRF2 as well as its downstream target genes were validated in HNSCC specimens. Moreover, the small interfering RNA (siRNA) targeting TNFAIP2 significantly enhanced the cisplatin treatment effect in a 4NQO-induced HNSCC mouse model. Our results reveal the antioxidant and cisplatin resistance-regulating roles of the TNFAIP2/KEAP1/NRF2/JNK axis in HNSCC, suggesting that TNFAIP2 might be a potential target in improving the cisplatin treatment effect, particularly for patients with cisplatin resistance.